{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:55:31Z","timestamp":1790931331984,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00259-026-08025-8","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T07:36:30Z","timestamp":1782372990000},"page":"6728-6737","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Inter- and intra-quartile comparison of multi-tracer PET\/CT and liquid biopsy molecular markers in cancer: a futuristic perspective on evolving a \u201cstepped care\u201d model for individualized precision theranostics through AI\/ML"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6607-2558","authenticated-orcid":false,"given":"Sandip","family":"Basu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam Kumar","family":"Ravada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul V.","family":"Parghane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aadil","family":"Adnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh K.","family":"Padwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhakti","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"8025_CR1","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","volume":"24","author":"F Bensch","year":"2018","unstructured":"Bensch F, et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018;24:1852\u20138.","journal-title":"Nat Med"},{"key":"8025_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41419-023-06391-x","volume":"15","author":"M Babamohamadi","year":"2024","unstructured":"Babamohamadi M, et al. Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy. Cell Death Dis. 2024;15:17.","journal-title":"Cell Death Dis"},{"key":"8025_CR3","doi-asserted-by":"crossref","unstructured":"Basu S, Parghane RV, Kamaldeep, Chakrabarty S. Peptide receptor radionuclide therapy of neuroendocrine tumors. Semin Nucl Med 2020;50:447\u2013464","DOI":"10.1053\/j.semnuclmed.2020.05.004"},{"key":"8025_CR4","first-page":"178","volume":"10","author":"S Basu","year":"2020","unstructured":"Basu S, et al. One decade of \u201cBench-to-Bedside\u201d peptide receptor radionuclide therapy with indigenous [(177)Lu]Lu-DOTATATE obtained through \u201cDirect\u201d neutron activation route: lessons learnt including practice evolution in an Indian setting. Am J Nucl Med Mol Imaging. 2020;10:178\u2013211.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"8025_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41416-022-02061-5","volume":"128","author":"DL Chan","year":"2023","unstructured":"Chan DL, et al. Dual [68Ga]DOTATATE and [18F]FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score. Br J Cancer. 2023;128:549\u201355.","journal-title":"Br J Cancer"},{"key":"8025_CR6","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/MNM.0000000000001371","volume":"42","author":"A Adnan","year":"2021","unstructured":"Adnan A, Basu S. Concept proposal for a six-tier integrated dual tracer PET-CT (68Ga-PSMA and FDG) image scoring system (\u201cPro-PET\u201d score) and examining its potential implications in metastatic castration-resistant prostate carcinoma theranostics and prognosis. Nucl Med Commun. 2021;42:566\u201374.","journal-title":"Nucl Med Commun"},{"key":"8025_CR7","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00259-020-05004-5","volume":"48","author":"RV Parghane","year":"2021","unstructured":"Parghane RV, et al. Long-term outcome of \u201csandwich\u201d chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease. Eur J Nucl Med Mol Imaging. 2021;48:913\u201323.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8025_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323.","journal-title":"N Engl J Med"},{"key":"8025_CR9","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14310\/horm.2002.1756","volume":"16","author":"G Treglia","year":"2017","unstructured":"Treglia G, Tamburello A, Giovanella L. Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis. Hormones (Athens). 2017;16:362\u201372.","journal-title":"Hormones (Athens)"},{"key":"8025_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00259-019-04458-6","volume":"47","author":"L Giovanella","year":"2020","unstructured":"Giovanella L, et al. EANM practice guideline for PET\/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2020;47:61\u201377.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8025_CR11","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, et al. (68)Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60:801\u20135.","journal-title":"J Nucl Med"},{"key":"8025_CR12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/MNM.0000000000000397","volume":"37","author":"S Basu","year":"2016","unstructured":"Basu S, Ranade R, Thapa P. 177Lu-DOTATATE versus 177Lu-EDTMP versus cocktail\/sequential therapy in bone-confined painful metastatic disease in medullary carcinoma of the thyroid and neuroendocrine tumour: can semiquantitative comparison of 68Ga-DOTATATE and 18F-fluoride PET-CT aid in personalized treatment decision making in selecting the best therapeutic option? Nucl Med Commun. 2016;37:100\u20132.","journal-title":"Nucl Med Commun"},{"key":"8025_CR13","doi-asserted-by":"publisher","unstructured":"Ravada SK, Parghane RV, Basu S. Multi-tracer PET reveals profound biological uncoupling in metastatic grade 3 pancreatic NET: beyond the Mib1 index. Eur J Nucl Med Mol Imaging. 2026. https:\/\/doi.org\/10.1007\/s00259-026-07913-3","DOI":"10.1007\/s00259-026-07913-3"},{"key":"8025_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s13139-019-00571-4","volume":"53","author":"S Ha","year":"2019","unstructured":"Ha S, Choi H, Paeng JC, Cheon GJ. Radiomics in oncological PET\/CT: a methodological overview. Nucl Med Mol Imaging. 2019;53:14\u201329.","journal-title":"Nucl Med Mol Imaging"},{"key":"8025_CR15","doi-asserted-by":"publisher","first-page":"4761","DOI":"10.1007\/s00259-025-07398-6","volume":"52","author":"S Basu","year":"2025","unstructured":"Basu S, Padwal MK, Parghane RV, Basu B. The promise of integrating omics-driven liquid biopsy and machine learning algorithms with multi-tracer PET in the management of neuroendocrine tumors: envisioning a panoptic model for precision oncology and molecular theranostics. Eur J Nucl Med Mol Imaging. 2025;52:4761\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8025_CR16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s13402-011-0025-9","volume":"34","author":"LA Muscarella","year":"2011","unstructured":"Muscarella LA, et al. Gene expression of somatostatin receptor subtypes SSTR2a, SSTR3 and SSTR5 in peripheral blood of neuroendocrine lung cancer affected patients. Cell Oncol (Dordr). 2011;34:435\u201341.","journal-title":"Cell Oncol (Dordr)"},{"key":"8025_CR17","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1002\/hed.28239","volume":"47","author":"K Chikamatsu","year":"2025","unstructured":"Chikamatsu K, et al. Detection of circulating cancer-associated fibroblasts in head and neck squamous cell carcinoma and their impact on circulating tumor cells. Head Neck. 2025;47:3141\u20139.","journal-title":"Head Neck"},{"key":"8025_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-02951-z","volume":"16","author":"H An","year":"2025","unstructured":"An H, An P. Single-cell and bulk RNA analysis identifies EMT-associated CAF signatures and prognostic model in lung adenocarcinoma. Discov Oncol. 2025;16:1106.","journal-title":"Discov Oncol"},{"key":"8025_CR19","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.62347\/VCCZ1477","volume":"16","author":"J Cui","year":"2024","unstructured":"Cui J, Zhou X, Sun S. Integration of bulk RNA-seq and single-cell RNA-seq constructs: a cancer-associated fibroblasts-related signature to predict prognosis and therapeutic response in clear cell renal cell carcinoma. Am J Transl Res. 2024;16:1081\u2013101.","journal-title":"Am J Transl Res"},{"key":"8025_CR20","first-page":"8279","volume":"16","author":"Z Fang","year":"2024","unstructured":"Fang Z, Han YL, Gao ZJ, Yao F. Cancer-associated fibroblast-derived gene signature discriminates distinct prognoses by integrated single-cell and bulk RNA-seq analyses in breast cancer. Aging (Albany NY). 2024;16:8279\u2013305.","journal-title":"Aging (Albany NY)"},{"key":"8025_CR21","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1159\/000548256","volume":"115","author":"N Zhou","year":"2025","unstructured":"Zhou N, et al. Circulating tumor DNA profiling identifies actionable mutations as prognostic markers in advanced neuroendocrine tumors. Neuroendocrinology. 2025;115:838\u201351.","journal-title":"Neuroendocrinology"},{"key":"8025_CR22","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1158\/2159-8290.CD-24-1509","volume":"15","author":"MN Sharifi","year":"2025","unstructured":"Sharifi MN, et al. High-purity CTC RNA sequencing identifies prostate cancer lineage phenotypes prognostic for clinical outcomes. Cancer Discov. 2025;15:969\u201387.","journal-title":"Cancer Discov"},{"key":"8025_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-36129-1","volume":"8","author":"M Sampedro-N\u00fa\u00f1ez","year":"2018","unstructured":"Sampedro-N\u00fa\u00f1ez M, et al. Analysis of expression of the PD-1\/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors. Sci Rep. 2018;8:17812.","journal-title":"Sci Rep"},{"key":"8025_CR24","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.2967\/jnumed.123.265391","volume":"64","author":"SA Esfahani","year":"2023","unstructured":"Esfahani SA, De Aguiar Ferreira C, Summer P, Mahmood U, Heidari P. Addition of peptide receptor radiotherapy to immune checkpoint inhibition therapy improves outcomes in neuroendocrine tumors. J Nucl Med. 2023;64:1056\u201361.","journal-title":"J Nucl Med"},{"key":"8025_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45475-w","volume":"15","author":"NM Fonseca","year":"2024","unstructured":"Fonseca NM, et al. Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer. Nat Commun. 2024;15:1828.","journal-title":"Nat Commun"},{"key":"8025_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov"},{"key":"8025_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000542918","volume":"115","author":"MK Padwal","year":"2024","unstructured":"Padwal MK, et al. Systemic cancer hallmarks as novel markers associated with progression-free survival in gastroenteropancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy. Neuroendocrinology. 2024;115:1\u201314.","journal-title":"Neuroendocrinology"}],"updated-by":[{"DOI":"10.1007\/s00259-026-08069-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000}}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08025-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08025-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08025-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:32:03Z","timestamp":1790929923000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08025-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8025"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08025-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The authors regret that the version of Figure 1 that appeared in the Springer Link website for this article is incorrect. The incorrect and correct version of Figure 1 are shown in the erratum article.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been corrected.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00259-026-08069-w","URL":"https:\/\/doi.org\/10.1007\/s00259-026-08069-w","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent participants","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No financial or non-financial assistance provided by a third party for the reported work.","order":3,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}